Why you should use PredictSURE IBD™
Without a prognostic test that stratifies patients based on risk, the standard of care is often a one-size fits all step-up approach. This may result in patients experiencing multiple flares causing bowel damage that can lead to disability and require surgical intervention (Figure A).
Controlling inflammation early can increase the chance of patients achieving long term remission, reducing flares, bowel damage and the need for surgery (Colombel, J-F et al 2017) (Figure B)
Using PredictSURE IBD allows you to identify patients at high-risk of early and frequent relapses, enabling you to optimise treatment strategy for each patient. You might choose the early use of aggressive therapy for patients at high-risk of frequent and early relapses, to maximise the chance of achieving remission and reducing the need for surgery in the long-term.
See our latest long-term validation data to see how PredictSURE IBD can help you identify high-risk patients.
Health Economic Impact
PredictImmune commissioned a health economic study to evaluate the economic impact of PredictSURE IBD on the UK Healthcare system. The model concluded that over the modelled period (20 years), the test delivered improved outcomes for both Crohn’s disease and ulcerative colitis with strong incremental cost-effectiveness ratio (ICER) for Crohn’s disease and potential cost savings for ulcerative colitis. More information in 2020 ECCO conference poster.